Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment, it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis recurrence, amputation and death approaching 52 % at one month if no specific treatment is initiated. It is therefore vital to diagnose HIT as early and as reliably as possible to permit appropriate management of this rare condition. During the acute phase of HIT, clinicians and biologists can only suspect this complication with a greater or lesser degree of confidence. Clinical data are not sufficiently sensitive or specific to confirm or refute thr diagnosis of HIT.
Purpose : To create and validate a score predicting the diagnosis of HIT
Study Type
OBSERVATIONAL
Enrollment
2,700
ETS de Franche Conté - Laboratoire d'Immuno Hématologie
Besançon, France
CHU Cavale Blanche Laboratoire d'Hématologie
Brest, France
Laboratoire d'hématologie - Hôpital Louis Pradel
Bron, France
Hôpital Antoine Beclère - Laboratoire d'hématologie
Clamart, France
Laboratoire d'hématologie - CHU de Clermont Ferrand
Clermont-Ferrand, France
HCC Colmar - laboratoire d'hématologie
Colmar, France
Laboratoire d'Hématologie - CHU le Bocage
Dijon, France
Laboratoire d'hémostase - CCML
Le Plessis-Robinson, France
Hôpital Cardiologique - Laboratoire d'Hémostase
Lille, France
CHU La Timone - Laboratoire Hématologie
Marseille, France
...and 17 more locations
the final diagnosis of HIT established by five independent experts in haemostasis and determined by thrombocytopenia and confirmation of HIT by immunological and/or functional tests
Time frame: inclusion and 40 days after the inclusion
pathogenic nature of anti HPF4 antibodies of IgM and IgA type
Time frame: inclusion
new biological test detecting HIT
Time frame: inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.